Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Sun Young Rha(Yonsei University), Kohei Shitara(National Cancer Center Hospital East), Chie‐Schin Shih(St Nicholas Hospital), Mehmet Bilici(Atatürk University), Patricio Yañez(Universidad de La Frontera), Sara Lonardi(Istituto Oncologico Veneto), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Akihito Kawazoe(National Cancer Center Hospital East), Shukui Qin(Memorial Sloan Kettering Cancer Center), Yuxian Bai(Harbin Medical University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Hyun Cheol Chung(Yonsei University), Kan Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lin Shen(Hangzhou Normal University), Jianming Xu(Chinese PLA General Hospital), Jean Phillipe Metges(Centre Hospitalier Régional Universitaire de Brest), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yuriy Ostapenko(National Cancer Institute), Josep Tabernero(Deaconess Hospital)
Cited by 461
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k